Teva Bets on Stem Cells, Cancer in $6.2 Billion Cephalon Bid..
Teva Pharmaceutical Industries Ltd., swooping in to outbid Valeant Pharmaceuticals International Inc. for Cephalon Inc., is counting on “high-risk, high-reward” stem-cell treatments and therapies for asthma and lung cancer to help it overcome growing competition to its biggest product.
The $6.2 billion deal gives Teva, which relies on the multiple sclerosis medicine Copaxone for 21 percent of its revenue, more than 30 compounds in late-stage trials. The pipeline will ensure future growth as Copaxone faces competition and Cephalon’s top-selling drug, the narcolepsy treatment Provigil, loses patent protection next April, Teva Chief Executive Officer Shlomo Yanai said.
Teva and Cephalon executives said they see potential in a therapy for congestive heart failure under development with Mesoblast Ltd., reslizumab for asthma and the lung-cancer treatment obatoclax. Teva needs two or three of Frazer, Pennsylvania-based Cephalon’s drugs to succeed to offset lost revenue once patent protection ends for the U.S. company’s top products, said Ori Hershkovitz, a partner at Sphera Global Healthcare Fund in Tel Aviv.
“Teva’s making four or five shots on goal with a very high-risk, high-reward kind of profile,” Hershkovitz said in an interview. Sphera owns Teva shares. “If they pull off the stem-cell product, they’re in the clear. But if they pull off two or three of the others, it would also be a very good deal.”
Branded Drugs
Teva will pay $81.50 a share in cash, 12 percent above Valeant’s March 29 offer, the Petah Tikva, Israel-based drugmaker said yesterday in a statement. Including assumed debt, the purchase values Cephalon at $6.8 billion. Valeant, based in Mississauga, Ontario dropped its plan to buy Cephalon after Teva announced its bid.
The deal will make Teva, the world’s biggest maker of generic drugs, less dependent on Copaxone for the branded portion of its business, Yanai said.
Cephalon said in some circumstances it may accept a better offer and, in certain instances, pay a fee of $275 million if it terminates the takeover, according to a company filing.
Cephalon rose $3.09, or 4 percent, to $80.11 at the 4 p.m. New York time close yesterday of Nasdaq Stock Market trading. Teva’s American depositary receipts climbed $1.54, or 3.4 percent, to $47.27. Valeant, based in Mississauga, Ontario, fell $3.05, or 5.8 percent, to $49.58 in New York Stock Exchange composite trading.
After the Valeant offer, Cephalon estimated that a dozen projects aiming to reach the market by 2016 may have peak sales of more than $9 billion combined. The company reported 2010 revenue of
$2.81 billion, of which $1.12 billion came from Provigil.
Cephalon has a better new-drug pipeline than Wall Street has given it credit for, Bill Marth, president of U.S. operations for Teva, said in a telephone interview.
‘Excited’
“Cephalon didn’t seem like they could get a break for the pipeline,” Marth said. “We are very excited about it and we think it will bear a lot of fruit.”
The deal gives Teva a 20 percent stake in Melbourne-based Mesoblast, a maker of stem-cell therapies, under a deal Cephalon signed in December. Revascor, an adult stem-cell therapy for congestive heart failure, a progressive weakening of the heart muscle, may revolutionize treatment if it’s effective, Hershkovitz said.
In a second-stage study in 60 heart failure patients, 45 patients who got the stem cells had fewer adverse cardiac events than 15 patients in a control group who didn’t, Cephalon announced in January. Therapies like Mesoblast’s aim to use adult human stem cells to replace and repair damaged tissue.
‘Consistent Results’
“We saw improvements in every cardiovascular measure we looked at,” said Kevin Buchi, chief executive officer of Cephalon, in a telephone interview yesterday. “It is a very small data set, but the consistent results across all the endpoints make us believe that these cells are doing something.” ..............Of course Kevin Buchi is now a director of MSB.......V
Expand
(20min delay)